# A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

> **NCT05786573** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Zenas BioPharma (USA), LLC** · enrollment: 134 (estimated)

## Conditions studied

- Warm Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** Obexelimab
- **DRUG:** Obexelimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05786573
- **Lead sponsor:** Zenas BioPharma (USA), LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-25
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-08-31
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05786573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05786573, "A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT05786573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*